The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients

Launched by CHULALONGKORN UNIVERSITY · Aug 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called the Double Plasma Molecular Adsorption System (DPMAS) for patients with acute-on-chronic liver failure, a serious condition where the liver fails suddenly on top of existing liver disease. The aim is to see if DPMAS can help improve the immune system and overall health of these patients by removing harmful substances and proteins from the blood that can worsen liver damage and lead to infections. The trial will compare the effects of DPMAS with standard treatments in patients who are admitted to the intensive care unit.

To participate in this trial, individuals must be 18 years or older and diagnosed with acute-on-chronic liver failure. They should also be in the intensive care unit for treatment. However, certain individuals are not eligible, such as pregnant women, those who have received steroids recently, or patients who are not expected to survive within 24 hours. Participants will receive either the DPMAS treatment or standard care and will be monitored closely to see how well the treatment works. This study could help find better ways to treat people with severe liver issues and improve their chances of recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 or more
• • 2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the study of the liver (APASL) criteria
• • 3. Admitted to intensive care unit
• Exclusion Criteria:
• • 1. Pregnancy
• • 2. Received steroid treatment
• • 3. Expected dead within 24 hour
• • 4. WBC \< 500/mm3
• • 5. Allergy to DPMAS
• • 6. History of organ transplant
• • 7. Terminal illness with do not resuscitation order